Cell, November 12-13, 2026

Meet Alphalyse at Cell 2026.

Protein impurities in cell and gene therapies arise upstream but surface downstream, where they can affect product quality and patient safety.

Regulators increasingly expect impurity analysis from early development, and LC-MS is becoming best practice for the complex protein profiles in AAV, lentiviral vector and cell therapy processes, where ELISA alone often falls short.

If you’re developing a cell or gene therapy and want to discuss what these evolving expectations mean for your program, come meet Ejvind, Valeria, and Elisabeth at Booth 29 at Cell 2026 in London, November 12–13, 2026.

Ejvind will also present Protein Impurities in Cell and Gene Therapies: Regulatory Expectations and LC-MS Best Practice on Thursday, November 12 at 09:45 in Conference Room 2.

We’re happy to talk about:

• Protein impurity characterization by LC-MS
  Identify and quantify individual host cell proteins and other protein impurities in your viral vector or cell therapy product, see which ones persist through purification, and flag the ones that matter for quality and safety.
• Risk classification to support your CMC package
  Classify each identified HCP by strength of evidence and flags high co-elution and critical enzyme activity.
• ELISA-MS™ for stronger HCP control strategies
  Evaluate your ELISA’s reagent coverage, uncover assay blind spots, and receive orthogonal data to support investigations, comparability studies during scale-up and tech transfer, and regulatory submissions.
• Outsourced LC-MS HCP analysis for CDMOs
  Expand your CGT analytical service offering with expert LC-MS-based HCP analysis without investing in new instrumentation, specialist staff, or in-house method development.

Send us a message below if you'd like to meet us at Cell 2026.